Search

Ranibizumab safety in pregnancy

Vascular endothelial growth factor (VEGF) plays a pivotal role during pregnancy, and systemic anti-VEGF administration during this period should thus be avoided. VEGF is expressed in multiple embryonic and foetal tissues during development, with the highest levels found in the...

Results of corneal cross-linking in very steep corneas

Corneal cross-linking (CXL) has been shown to be a safe and valid treatment option for progressive keratoconus and have shown an arrest of progression with a low failure rate of 0% to 2.8% in mild to moderate keratoconus. A Kmax...

Elevated risk of mood disorders after recurrent retinal detachment

This study was aimed to investigate the risk of mood disorders in patients who experienced retinal detachment (RD) by using the National Health Insurance Research Database in Taiwan. A total of 4129 participants diagnosed with RD and 16,516 non-RD individuals...

Verteporfin shortage: treatment options and outcomes in chronic non-resolving central serous chorioretinopathy

Half-dose photodynamic therapy (HD-PDT) with verteporfin has been the therapy of choice in non-resolving central serous chorioretinopathy lasting longer than four months. Since 2021, a worldwide shortage of verteporfin due to manufacturing issues prompted adjustments in treatment practices. This retrospective,...

Two-year GATHER2 data: anatomical gains, functional questions for avacincaptad pegol in geographic atrophy

Geographic atrophy (GA) secondary to age-related macular degeneration (AMD) remains a leading cause of irreversible central vision loss, and complement dysregulation has long been implicated in its pathogenesis. In 2023, the US FDA approved the first two GA therapies, both...